Literature DB >> 8430682

Budd-Chiari syndrome in autosomal dominant polycystic kidney disease: a complication of nephrectomy in patients with liver cysts.

D M Clive1, A Davidoff, R T Schweizer.   

Abstract

We report two patients with autosomal dominant polycystic kidney disease (ADPKD) who developed the Budd-Chiari syndrome following bilateral nephrectomy. Both patients had massive cystic enlargement of the liver. Neither had any other identifiable risk factors for the Budd-Chiari syndrome. We suggest that removal of the kidneys may predispose toward anatomic obstruction of the inferior vena cava or hepatic veins by liver cysts. Nephrectomy should be approached cautiously in ADPKD patients with extensive involvement of the liver by cysts.

Entities:  

Mesh:

Year:  1993        PMID: 8430682     DOI: 10.1016/s0272-6386(12)81094-8

Source DB:  PubMed          Journal:  Am J Kidney Dis        ISSN: 0272-6386            Impact factor:   8.860


  4 in total

1.  Inferior vena cava stenting: a safe and effective treatment for intractable ascites in patients with polycystic liver disease.

Authors:  Jayleen Grams; Swee H Teh; Vicente E Torres; James C Andrews; David M Nagorney
Journal:  J Gastrointest Surg       Date:  2007-08       Impact factor: 3.452

2.  Functional Budd-Chiari Syndrome Associated With Severe Polycystic Liver Disease.

Authors:  Precil Diego Miranda de Menezes Neves; Bruno Eduardo Pedroso Balbo; Elieser Hitoshi Watanabe; Vinicius Rocha-Santos; Wellington Andraus; Luiz Augusto Carneiro D'Albuquerque; Luiz Fernando Onuchic
Journal:  Clin Med Insights Gastroenterol       Date:  2017-06-07

3.  Pleuritic chest pain from portal hypertensive gastropathy in ESRD patient with autosomal dominant polycystic kidney disease misdiagnosed as pericarditis.

Authors:  Macaulay Amechi Chukwukadibia Onuigbo; Nneoma Agbasi; Jennifer Achebe; Charles Odenigbo; Fidelis Oguejiofor
Journal:  J Renal Inj Prev       Date:  2016-01-30

Review 4.  Management of portal hypertension and ascites in polycystic liver disease.

Authors:  Lucas H P Bernts; Joost P H Drenth; Eric T T L Tjwa
Journal:  Liver Int       Date:  2019-09-20       Impact factor: 5.828

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.